These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 26735339)

  • 1. Valproic acid potentiates the anticancer activity of capecitabine in vitro and in vivo in breast cancer models via induction of thymidine phosphorylase expression.
    Terranova-Barberio M; Roca MS; Zotti AI; Leone A; Bruzzese F; Vitagliano C; Scogliamiglio G; Russo D; D'Angelo G; Franco R; Budillon A; Di Gennaro E
    Oncotarget; 2016 Feb; 7(7):7715-31. PubMed ID: 26735339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase.
    Di Gennaro E; Piro G; Chianese MI; Franco R; Di Cintio A; Moccia T; Luciano A; de Ruggiero I; Bruzzese F; Avallone A; Arra C; Budillon A
    Br J Cancer; 2010 Nov; 103(11):1680-91. PubMed ID: 21045833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lidamycin up-regulates the expression of thymidine phosphorylase and enhances the effects of capecitabine on the growth and pulmonary metastases of murine breast carcinoma.
    Zhang SH; Zhang H; He HW; Li L; Li XQ; Zhang YP; Shao RG
    Cancer Chemother Pharmacol; 2013 Oct; 72(4):777-88. PubMed ID: 23975242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone deacetylase inhibitors induce thymidine phosphorylase expression in cultured breast cancer cell lines.
    Puppin C; Puglisi F; Pandolfi M; Di Loreto C; Damante G
    Oncol Rep; 2011 Aug; 26(2):309-14. PubMed ID: 21617864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models.
    Ouchi KF; Yanagisawa M; Sekiguchi F; Tanaka Y
    Cancer Chemother Pharmacol; 2006 May; 57(5):693-702. PubMed ID: 16362295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Positive interaction between lapatinib and capecitabine in human breast cancer models: study of molecular determinants.
    Chefrour M; Milano G; Formento P; Giacometti S; Denden A; Renée N; Iliadis A; Fischel JL; Ciccolini J
    Fundam Clin Pharmacol; 2012 Aug; 26(4):530-7. PubMed ID: 21623901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autophagy induction causes a synthetic lethal sensitization to ribonucleotide reductase inhibition in breast cancer cells.
    Chen YR; Tsou B; Hu S; Ma H; Liu X; Yen Y; Ann DK
    Oncotarget; 2016 Jan; 7(2):1984-99. PubMed ID: 26675256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5-Ethoxy-2'-deoxyuridine, a novel substrate for thymidine phosphorylase, potentiates the antitumor activity of 5-fluorouracil when used in combination with interferon, an inducer of thymidine phosphorylase expression.
    Schwartz EL; Baptiste N; Megati S; Wadler S; Otter BA
    Cancer Res; 1995 Aug; 55(16):3543-50. PubMed ID: 7627962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Valproic acid (VPA) inhibits the epithelial-mesenchymal transition in prostate carcinoma via the dual suppression of SMAD4.
    Lan X; Lu G; Yuan C; Mao S; Jiang W; Chen Y; Jin X; Xia Q
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):177-85. PubMed ID: 26206483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human melatonin MT1 receptor induction by valproic acid and its effects in combination with melatonin on MCF-7 breast cancer cell proliferation.
    Jawed S; Kim B; Ottenhof T; Brown GM; Werstiuk ES; Niles LP
    Eur J Pharmacol; 2007 Mar; 560(1):17-22. PubMed ID: 17303109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Schedule dependency of antitumor activity in combination therapy with capecitabine/5'-deoxy-5-fluorouridine and docetaxel in breast cancer models.
    Fujimoto-Ouchi K; Tanaka Y; Tominaga T
    Clin Cancer Res; 2001 Apr; 7(4):1079-86. PubMed ID: 11309360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of sensitivity to capecitabine in human renal carcinoma cells transfected with thymidine phosphorylase cDNA.
    Morita T; Matsuzaki A; Tokue A
    Int J Cancer; 2001 May; 92(3):451-6. PubMed ID: 11291085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of thymidine phosphorylase in both irradiated and shielded, contralateral human U87MG glioma xenografts: implications for a dual modality treatment using capecitabine and irradiation.
    Blanquicett C; Gillespie GY; Nabors LB; Miller CR; Bharara S; Buchsbaum DJ; Diasio RB; Johnson MR
    Mol Cancer Ther; 2002 Oct; 1(12):1139-45. PubMed ID: 12481438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Hollow Fibre Assay as a model for in vivo pharmacodynamics of fluoropyrimidines in colon cancer cells.
    Temmink OH; Prins HJ; van Gelderop E; Peters GJ
    Br J Cancer; 2007 Jan; 96(1):61-6. PubMed ID: 17179993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Making capecitabine targeted therapy for breast cancer: which is the role of thymidine phosphorylase?
    Bonotto M; Bozza C; Di Loreto C; Osa EO; Poletto E; Puglisi F
    Clin Breast Cancer; 2013 Jun; 13(3):167-72. PubMed ID: 23218471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potentiation of anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the cyclin-dependent kinase inhibitor P276-00 in human non-small-cell lung cancer cell lines.
    Shirsath N; Rathos M; Chaudhari U; Sivaramakrishnan H; Joshi K
    Lung Cancer; 2013 Nov; 82(2):214-21. PubMed ID: 24051085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic antitumor interaction between valproic acid, capecitabine and radiotherapy in colorectal cancer: critical role of p53.
    Terranova-Barberio M; Pecori B; Roca MS; Imbimbo S; Bruzzese F; Leone A; Muto P; Delrio P; Avallone A; Budillon A; Di Gennaro E
    J Exp Clin Cancer Res; 2017 Dec; 36(1):177. PubMed ID: 29212503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of thymidine phosphorylase expression by using an HSP90 inhibitor potentiates the cytotoxic effect of cisplatin in non-small-cell lung cancer cells.
    Weng SH; Tseng SC; Huang YC; Chen HJ; Lin YW
    Biochem Pharmacol; 2012 Jul; 84(1):126-36. PubMed ID: 22480737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DCA increases the antitumor effects of capecitabine in a mouse B16 melanoma allograft and a human non-small cell lung cancer A549 xenograft.
    Zheng MF; Shen SY; Huang WD
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1031-41. PubMed ID: 24043136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the anticancer properties of a novel valproic acid prodrug to leading histone deacetylase inhibitors.
    Tarasenko N; Chekroun-Setti H; Nudelman A; Rephaeli A
    J Cell Biochem; 2018 Apr; 119(4):3417-3428. PubMed ID: 29135083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.